Dr. Raymond Wee, MD
Ophthalmology (Ophthalmology Physician)
98-1079 Moanalua Road, Suite 470
Aiea, HI 96701
Who else practices at this address →
Honolulu County includes primary care (9% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- Washington University School of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 975
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: Washington University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Ophthalmology Physician primary
HI license MD15506 · MO license 2008009375
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Retina Consultants of Hawaii Inc (5 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 975
- Services billed
- 28,489
- Patients’ average age
- 77
| Service | Times | Patients |
|---|---|---|
| Injection, faricimab-svoa, 0.1 mg | 12,424 | 49 |
| Imaging of retina | 1,880 | 827 |
| Injection of drug into eye | 1,252 | 261 |
| Established patient complete exam of visual system | 1,142 | 848 |
| Injection, aflibercept, 1 mg | 1,076 | 114 |
| Established patient problem focused exam of visual system | 826 | 289 |
| Compounded drug, not otherwise classified | 448 | 110 |
| Photography of the retina | 165 | 146 |
| New patient office or other outpatient visit, 45-59 minutes | 127 | 127 |
| Injection, ranibizumab, 0.1 mg | 123 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Prednisolone Acetate Other prescribers in Aiea, HI | 97 |
| Moxifloxacin (moxifloxacin hcl) Other prescribers in Aiea, HI | 65 |
| Bromfenac Sodium | 49 |
| Pilocarpine Hcl Other prescribers in Aiea, HI | 22 |
| Ciprofloxacin Hcl Other prescribers in Aiea, HI | 20 |
| Prolensa (bromfenac sodium) | 14 |
| Ketorolac Tromethamine Other prescribers in Aiea, HI | 14 |
| Brimonidine Tartrate Other prescribers in Aiea, HI | 13 |
| Timolol Maleate Other prescribers in Aiea, HI | 13 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 9 payments worth $812 in total to this clinician.
| Alcon Vision LLC | $251 |
|---|---|
| Genentech USA, Inc. | $177 |
| Amgen Inc. | $135 |
| Tarsus Pharmaceuticals, Inc. | $134 |
| Mallinckrodt Hospital Products Inc. | $115 |
| Food and Beverage | $812 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $473,474 in research payments for these studies, mostly to the institutions running them.
- A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME)
Regeneron Pharmaceuticals, Inc. · Active, not recruiting · NCT06491914 - Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease
Regeneron Pharmaceuticals, Inc. · Completed · NCT04429503 - CRIMSON: A multicentre, randomised, sham-controlled (and active controlled in the USA), double-masked, 72-week trial to study the safety, tolerability, pharmacokinetics, and efficacy of 3 dosing regimens of intravitre…
Boehringer Ingelheim International GmbH - A Phase 3 Randomized, Double-Masked, Active-Controlled Study of the Efficacy and Safety of 8 MG Aflibercept in Participants with Macular Edema Following Retinal Vein Occlusion
Regeneron Pharmaceuticals, Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.